The Lancet General Medicine

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →